Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 5/20 | 0.39 |
| ▸ | BRD4 | O60885 | 4/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.38 |
| ▸ | AQP1 | P29972 | 2/20 | 0.36 |
| ▸ | PARP1 | P09874 | 3/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 3/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4595334 | 0.87 | PARP1 (0.41) | HTR1ABRD4CREBBPAQP1PARP1 | |
| SCHEMBL4596991 | 0.85 | HTR2A (0.37) | AQP1HTR2AHTR2C | |
| SCHEMBL4234706 | 0.83 | AQP1 (0.51) | AQP1HTR2AHTR2C | |
| SCHEMBL4713784 | 0.82 | HTR1A (0.42) | HTR1ABRD4CREBBPAQP1PARP1 | |
| SCHEMBL4597019 | 0.82 | LMNA (0.38) | HTR1ABRD4CREBBPPARP1KDM4E | |
| SCHEMBL4230246 | 0.81 | AQP1 (0.41) | AQP1HTR2AHTR2C | |
| SCHEMBL4230242 | 0.81 | AQP1 (0.58) | AQP1HTR2AHTR2C | |
| SCHEMBL4710012 | 0.81 | GPBAR1 (0.38) | HTR1ABRD4CREBBPPARP1MAOA | |
| SCHEMBL4596982 | 0.80 | AQP1 (0.50) | HTR1ABRD4CREBBPAQP1PARP1 | |
| SCHEMBL4596590 | 0.80 | HTR1A (0.38) | HTR1ABRD4CREBBPAQP1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1898895-A2 | TREATMENT OF DRUG ABUSE | Wyeth (US) | 2008-03-19 | — | — | EP | claimed |
| JP-2007509174-A | — | — | 2007-04-12 | — | — | JP | claimed |
| WO-2006116148-A2 | (7-ARLYSUBSTITUTED 2, 3-DIHYDR0-1-BENZ0FURAN-2-YL) ALKYLAMINES IN THE TREATMENT' OF SUBSTANCE ABUSE | WYETH (US) | 2006-11-02 | — | — | WO | claimed |
| EP-1675840-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | Wyeth a Corporation of the State of Delaware (US) | 2006-07-05 | — | — | EP | claimed |
| WO-2005044812-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | WYETH A CORPORATION OF THE STATE OF DELAWARE (US) | 2005-05-19 | — | — | WO | claimed |
| EP-1998764-A2 | METHODS FOR TREATING COGNITIVE AND OTHER DISORDERS | Wyeth a Corporation of the State of Delaware (US) | 2008-12-10 | — | — | EP | disclosed |
| EP-1879569-A2 | THERAPEUTIC COMBINATIONS FOR THE TREATMENT OR PREVENTION OF PSYCHOTIC DISORDERS | Wyeth (US) | 2008-01-23 | — | — | EP | disclosed |
| EP-1874750-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | Wyeth Incoporated (US) | 2008-01-09 | — | — | EP | disclosed |
| WO-2007112065-A2 | METHODS FOR TREATING COGNITIVE AND OTHER DISORDERS | WYETH (US) | 2007-10-04 | — | — | WO | disclosed |
| WO-2006116221-A2 | THERAPEUTIC COMBINATIONS FOR THE TREATMENT OR PREVENTION OF PSYCHOTIC DISORDERS | WYETH (US) | 2006-11-02 | — | — | WO | disclosed |
| EP-1675840-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | Wyeth a Corporation of the State of Delaware (US) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005044812-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | WYETH A CORPORATION OF THE STATE OF DELAWARE (US) | 2005-05-19 | — | — | WO | disclosed |